Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like DexCom Reports First Quarter 2017 Financial Results May 2, 2017 Two Drugmakers Compete for Sanofi's $2.4B Generics Biz February 5, 2018 Health Insurer Cigna Paying $67 Billion to Buy Express Script March 7, 2018
